Skip to main content
Contact Us
Subscribe
E-Edition
31°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2024
Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
OKYO Pharma Limited - Ordinary Shares
(NQ:
OKYO
)
1.060
-0.030 (-2.75%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about OKYO Pharma Limited - Ordinary Shares
< Previous
1
2
3
4
5
6
7
8
Next >
12 Health Care Stocks Moving In Friday's After-Market Session
March 01, 2024
Via
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
February 12, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
February 09, 2024
Via
Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
February 09, 2024
Via
Benzinga
OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
February 09, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
January 31, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
12 Health Care Stocks Moving In Monday's After-Market Session
January 08, 2024
Via
Benzinga
OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
January 08, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
January 05, 2024
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
December 04, 2023
Top-line Efficacy and Safety Data on Track for Release in December 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction
October 31, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Dow Rebounds, Still Below Fair Value
October 09, 2023
The Israeli-Palestinian conflict is in focus worldwide, after erupting into a deadly war over the weekend.
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
OKYO Pharma Announces Filing of an Investigational New Drug (IND) Application for OK-101 to Treat Neuropathic Corneal Pain (“NCP”)
October 09, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's After-Market Session
October 05, 2023
Via
Benzinga
Why Accolade Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
October 05, 2023
Gainers Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by Japan's Kyowa Kirin for $16.00 per ADS in cash plus an additional contingent...
Via
Benzinga
Dry Eye Disease Affects Around 50M Americans, OKYO Pharma's Candidate Shows Safety In Mid-Stage Study
October 05, 2023
OKYO Pharma Limited (NASDAQ: OKYO) announced that its first drug candidate, OK-101, presently in a 240-patient phase 2 trial in patients with dry eye disease (DED) is currently showing a positive...
Via
Benzinga
OKYO Pharma Announces Positive Safety Data Profile for the ongoing OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease ("DED")
October 05, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma’s Advancing Clinical Mission to Better Treat Eye Disease Sends Shares 89% Higher Since August ($OKYO)
October 05, 2023
Via
AB Newswire
12 Health Care Stocks Moving In Tuesday's After-Market Session
September 19, 2023
Via
Benzinga
Why Nikola Shares Are Trading Higher By 33%? Here Are Other Stocks Moving In Monday's Mid-Day Session
September 18, 2023
Gainers
Via
Benzinga
Why Rubicon Technologies Shares Are Trading Lower By Over 7%; Here Are 20 Stocks Moving Premarket
September 18, 2023
Gainers T2 Biosystems, Inc. (NASDAQ: TTOO) shares rose 44.4% to $0.4003 in pre-market trading. T2 Biosystems said it issued inducement awards to four new employees.
Via
Benzinga
Why Volcon Shares Are Trading Lower By 19%; Here Are 20 Stocks Moving Premarket
September 15, 2023
Gainers AgriFORCE Growing Systems Ltd. (NASDAQ: AGRI) shares rose 38.7% to $0.1421 in pre-market trading after gaining 10% on Thursday.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
September 15, 2023
We're starting the final day of trading this week with a breakdown of the biggest pre-market stock movers for Friday morning!
Via
InvestorPlace
OKYO Pharma Announces Closing of $4.0 Million Registered Direct Offering of Ordinary Shares
September 15, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Why Clearmind Medicine Shares Are Trading Lower By 53%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
September 14, 2023
Gainers First Wave BioPharma, Inc. (NASDAQ: FWBI) shares jumped 89.5% to $0.8243 after the company announced license agreement for capeserod from Sanofi.
Via
Benzinga
OKYO Pharma Announces Pricing of $4.0 Million Registered Direct Offering of Ordinary Shares
September 14, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
OKYO Pharma Limited Announces Withdrawal of Public Offering
September 14, 2023
From
OKYO Pharma LTD
Via
GlobeNewswire
Why Novo Integrated Sciences Shares Are Trading Higher By 9%; Here Are 20 Stocks Moving Premarket
September 14, 2023
Gainers TransCode Therapeutics, Inc. (NASDAQ: RNAZ) shares rose 43.3% to $1.29 in pre-market trading.
Via
Benzinga
Nasdaq, S&P 500 Futures In Green As Traders Look Past Inflation Data; Analyst Singles Out Key Catalyst That Can Keep Year's Rally Going
September 14, 2023
US stocks could open Thursday's session higher, apparently in relief rally following the August inflation data.
Via
Benzinga
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
12 Health Care Stocks Moving In Wednesday's After-Market Session
September 13, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.